Search

Your search keyword '"McAlarnen, Lindsey A."' showing total 37 results
Start Over Author "McAlarnen, Lindsey A."
37 results on '"McAlarnen, Lindsey A."'

11. An open label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer.

Author

Bradley, William Hampton, primary, Hayes, Monica Prasad, additional, Taylor, Nicolas, additional, Rader, Janet Sue, additional, Bishop, Erin, additional, Hopp, Elizabeth, additional, McAlarnen, Lindsey Allison, additional, Liegl, Melodee, additional, Simpson, Pippa, additional, and Uyar, Denise, additional

Published
2022
Full Text
View/download PDF

12. Correction: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers 2022, 14, 958

Author

Parashar, Deepak, primary, Geethadevi, Anjali, additional, Mittal, Sonam, additional, McAlarnen, Lindsey A., additional, George, Jasmine, additional, Kadamberi, Ishaque P., additional, Gupta, Prachi, additional, Uyar, Denise S., additional, Hopp, Elizabeth E., additional, Drendel, Holli, additional, Bishop, Erin A., additional, Bradley, William H., additional, Bone, Kathleen M., additional, Rader, Janet S., additional, Pradeep, Sunila, additional, and Chaluvally-Raghavan, Pradeep, additional

Published
2022
Full Text
View/download PDF

13. Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer

Author

Gupta, Prachi, primary, Kadamberi, Ishaque Pulikkal, additional, Mittal, Sonam, additional, Tsaih, Shirng‐Wern, additional, George, Jasmine, additional, Kumar, Sudhir, additional, Vijayan, Dileep K., additional, Geethadevi, Anjali, additional, Parashar, Deepak, additional, Topchyan, Paytsar, additional, McAlarnen, Lindsey, additional, Volkman, Brian F, additional, Cui, Weiguo, additional, Zhang, Kam Y. J., additional, Di Vizio, Dolores, additional, Chaluvally‐Raghavan, Pradeep, additional, and Pradeep, Sunila, additional

Published
2022
Full Text
View/download PDF

14. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance

Author

Parashar, Deepak, primary, Geethadevi, Anjali, additional, Mittal, Sonam, additional, McAlarnen, Lindsey, additional, George, Jasmine, additional, Kadamberi, Ishaque, additional, Gupta, Prachi, additional, Uyar, Denise, additional, Hopp, Elizabeth, additional, Drendel, Holli, additional, Bishop, Erin, additional, Bradley, William, additional, Bone, Kathleen, additional, Rader, Janet, additional, Pradeep, Sunila, additional, and Chaluvally-Raghavan, Pradeep, additional

Published
2022
Full Text
View/download PDF

16. Challenges of Reaching Patients With Cancer on Social Media: Lessons From the Failed #CancerRealTalk Experience.

Author

Beltrán Ponce, Sara, McAlarnen, Lindsey A., and Teplinsky, Eleonora

Subjects
SOCIAL media, PHYSICIAN-patient relations, SERIAL publications, CANCER patients, COMMUNICATION, HEALTH, INFORMATION resources, MISINFORMATION
Abstract

The article presents the discussion on physicians or other health care professionals having a high risk of containing misinformation. Topics include instantaneous access to medical information being beneficial and empowering patients to advocate and others in the cancer communities; and having dietary recommendations in cancer treatment and survivorship.

Published
2023
Full Text
View/download PDF

21. Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers

Author

McAlarnen,Lindsey, Stearns,Kristen, and Uyar,Denise

Subjects
The Application of Clinical Genetics
Abstract

Lindsey McAlarnen, Kristen Stearns, Denise Uyar Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USACorrespondence: Denise UyarDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226, USATel +1 414-805-6606Fax +1 414-805-6622Email duyar@mcw.eduAbstract: Completion of genetic testing is increasingly important for the complex care of patients with suspected hereditary breast and ovarian cancers (HBOC) and their at-risk family members. Identification of individuals with pathogenic variants has implications for targeted treatment recommendations, risk reduction strategies, increased surveillance recommendations, as well as the genetic testing of family members, known as cascade testing or screening. Due to advances in technology and decreasing costs, what was once single-gene genetic testing has evolved into large-scale multi-gene panel genomic testing. As germline genomic testing for HBOC becomes more and more available, it is important to identify the challenges that are associated with its use. In this manuscript, we review the current issues faced by germline genomic testing for HBOC which include effectively managing the marked increases in genetic referrals, interpreting the vast amount of information yielded by newer testing methods such as next generation sequencing (NGS), recognizing the need for better cascade screening strategies, potential exacerbation of health disparities and improving support for patients navigating the emotional impact related to positive, negative and indeterminate testing results.Keywords: genetic testing, genomic testing, hereditary breast and ovarian cancer syndrome, BRCA, cascade testing, next-generation sequencing

Published
2021

29. Laparoscopic techniques for Essure device removal

Author

Yang, Linda C., McAlarnen, Lindsey, and McKenna, Mary

Subjects
Laparoscopy -- Methods, Surgery, Health, Essure (Contraceptive)
Abstract

In this video, the authors illustrate laparoscopic techniques for Essure removal using a 4-step approach as well as a simplified method of specimen removal. The 4 steps include understanding the [...]

Published
2020

36. Same-Day Discharge After Robotic Hysterectomy: A Resource Utilization and Quality Improvement Project.

Author

McAlarnen LA, Maurer JE, Knaub A, Hopp E, Streitenberger K, Bishop E, Bradley W, Rader J, and Uyar D

Subjects
Humans, Female, Patient Discharge, Quality Improvement, Retrospective Studies, Hysterectomy, Postoperative Complications, Robotic Surgical Procedures, Laparoscopy
Abstract

Background: We implemented a low-cost education initiative to improve the rate of same-day discharge following hysterectomy performed for malignancy and assessed feasibility and impact on resource utilization., Methods: Development and implementation of faculty, patient, clinical, and perioperative staff education regarding the goal of same-day discharge for patients undergoing robotic hysterectomy and staging by gynecologic oncologists was started in July 2019. Chart review of 103 patients prior to the intervention and 112 patients after the start of the intervention was completed., Results: The rate of same-day discharge increased from 5% to 32% following the low-cost process change initiative, and a total of approximately 682 inpatient care hours were saved per 31 patients., Discussion: The rate of same-day discharges after hysterectomy and staging performed by gynecologic oncologists can be safely increased with a simple educational intervention, which can save significant patient care resources., (Copyright© Board of Regents of the University of Wisconsin System and The Medical College of Wisconsin, Inc.)

Published
2022

37. Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies.

Author

McAlarnen LA, Gupta P, Singh R, Pradeep S, and Chaluvally-Raghavan P

Abstract

Ovarian cancer most commonly presents at an advanced stage where survival is approximately 30% compared with >80% if diagnosed and treated before disease spreads. Diagnostic capabilities have progressed from surgical staging via laparotomy to image-guided biopsies and immunohistochemistry staining, along with advances in technology and medicine. Despite improvements in diagnostic capabilities, population-level screening for ovarian cancer is not recommended. Extracellular vesicles (EVs) are 40-150 nm structures formed when the cellular lipid bilayer invaginates. These structures function in cell signaling, immune responses, cancer progression, and establishing the tumor microenvironment. EVs are found in nearly every bodily fluid, including serum, plasma, ascites, urine, and effusion fluid, and contain molecular cargo from their cell of origin. This cargo can be analyzed to yield information about a possible malignancy. In this review we describe how the cargo of EVs has been studied as biomarkers in ovarian cancer. We bring together studies analyzing evidence for various cargos as ovarian cancer biomarkers. Then, we describe the role of EVs in modulation of the tumor microenvironment. This review also summarizes the therapeutic and translational potential of EVs for their optimal utilization as non-invasive biomarkers for novel treatments against cancer., Competing Interests: The authors declare no competing interests., (© 2022 The Author(s).)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results